MedTrace Logo

The Comparison Between M-E-BCS and C-O-BCS.

NCT07539545 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1366

Last updated 2026-04-20

No results posted yet for this study

Summary

This study is a multicenter, open-label, randomized controlled trial. The study aims to evaluate differences in operative efficiency (e.g., operative time), economic effect, surgical safety (e.g., surgical complication rates), postoperative aesthetics (e.g., BREAST-Q scores, Harris scores, SCAR-Q scores and Ueda scores), and oncological safety (e.g., margin status, no local recurrence survival) between patients undergoing M-E-BCS and patients undergoing C-O-BCS.

Conditions

Interventions

PROCEDURE

Minimal accessory-incision-assisted endoscopic breast-conserving surgery

A small incision was made in the concealed area of the armpit, and a endoscopic device was inserted. Under direct vision, the tumor was precisely removed and the lymph nodes in the armpit were cleared layer by layer. The incision was then sutured layer by layer, and a drainage tube was placed after the operation.

PROCEDURE

Conventional open breast-conserving surgery

Conventional open breast-conserving surgery is a surgical approach that aims to preserve the appearance and function of the breast as much as possible while ensuring the complete removal of the tumor. It is suitable for eligible patients with early-stage breast cancer and requires comprehensive postoperative treatment measures such as radiotherapy.

Sponsors & Collaborators

  • West China Fourth Hospital of Sichuan University

    collaborator UNKNOWN

  • West China Second University Hospital

    collaborator OTHER

  • The Fourth People's Hospital of Sichuan Province

    collaborator UNKNOWN

  • Taiyuan Central Hospital of Shanxi Medical University

    collaborator OTHER

  • Chengdu Second people's hospital

    collaborator UNKNOWN

  • Suzhou Municipal Hospital

    collaborator OTHER

  • Du Zhenggui

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2032-12-01
Completion
2032-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07539545 on ClinicalTrials.gov